Income Statement

Modulight's revenue growth in the last quarter has been driven by the increasing adoption of its products in various clinical applications, particularly in oncology and ophthalmology. The company's ability to expand its product portfolio and enter new markets has also contributed to its revenue growth. Furthermore, Modulight's focus on developing high-quality, user-friendly products has led to a significant increase in customer satisfaction and repeat business. The company's strategic partnerships and collaborations with key stakeholders have also played a crucial role in driving revenue growth. Looking ahead, Modulight's strong pipeline of new products and its continued investment in research and development are expected to drive further revenue growth and expansion into new markets.

The realised revenue for Q2 2026 is 1.6 million Euros, and the predicted revenue for Q2 2027 (e) is 1.5 million Euros. The revenue is expected to decrease by 0.1 million Euros, which is a 6.25% decrease from the realised value. The revenue is expected to decrease by 0.9 million Euros from 2025 to 2026, which is a 12.7% decrease. From 2026 to 2027, the revenue is expected to decrease by 0.1 million Euros, which is a 1.7% decrease. The annual revenue values are 7.1 million Euros in 2025, 6.1 million Euros in 2026, and 6.0 million Euros in 2027.

Modulight's EBIT profitability has shown a significant improvement, indicating a positive trend in the company's operational efficiency. This development can be attributed to the company's focus on optimizing its business processes, which has led to a reduction in costs and an increase in productivity. Additionally, Modulight's strategic investments in research and development have enabled the company to enhance its product offerings, resulting in higher margins and improved profitability. The company's ability to scale its operations and expand its customer base has also contributed to its improved EBIT profitability. Overall, Modulight's efforts to streamline its operations and enhance its product portfolio have paid off, leading to a notable improvement in its EBIT profitability.

The realised Ebit for Q2 2026 is -1.3 million Euros, while the predicted Ebit for Q2 2027 (e) is -2.2 million Euros. The expected change in Ebit from Q2 2026 to Q2 2027 (e) is a decrease of 0.9 million Euros, which represents a 69.2% decrease. The expected change in Ebit from 2025 to 2026 is a decrease of 0.3 million Euros, which is a 6.5% drop. From 2026 to 2027, the expected change is a decrease of 0.6 million Euros, which is a 12.2% drop. The annual Ebit values for the years 2025, 2026, and 2027 are -4.6, -4.9, and -5.5 million Euros, respectively.

The realised profit before tax in Q2 2026 is -1.4 million Euros, and the predicted profit before tax in Q2 2027 (e) is -2.2 million Euros. The expected change in profit before tax from Q2 2026 to Q2 2027 (e) is a decrease of 0.8 million Euros, which is a 57.1% decrease. The expected change in Profit before tax from 2025 to 2026 is a decrease of 0.2 million Euros, which is a 4.3% decrease. From 2026 to 2027, the expected change is a decrease of 0.7 million Euros, which is a 14.6% decrease. The annual values for Profit before tax are -4.6 million Euros in 2025, -4.8 million Euros in 2026, and -5.5 million Euros in 2027.

The realised profit for Q2 2026 is -1.4 million Euros, while the predicted profit for Q2 2027 (e) is -1.8 million Euros. The expected change in profit from Q2 2026 to Q2 2027 (e) is a decrease of 0.4 million Euros, which represents a 28.6% decrease. The expected change in profit from 2025 to 2026 is a decrease of 0.3 million Euros, which is a 6.5% decrease. From 2026 to 2027, the expected change is a decrease of 0.1 million Euros, which is a 2.3% decrease. The annual profit values are -4.6 million Euros in 2025, -4.3 million Euros in 2026, and -4.4 million Euros in 2027.